|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
22.07.26 - 13:03
|
Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman (GlobeNewswire EN)
|
|
|
BOSTON, July 22, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr. Gabriele Cerrone, through Panetta Partners Ltd, an entity in which he has a beneficial interest, has increased his holdings with the purchase of 42,357 common shares at $0.99 per share, bringing his total holding to 44,814,587 common shares, which is 34.93% of issued share capital....
|
|
|
|
|
28.05.26 - 13:03
|
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York (GlobeNewswire EN)
|
|
|
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that it will present at the Jefferies Global Healthcare Conference taking place in New York City. Ivor Elrifi, Chief Executive Officer and Keeren Shah, Chief Operating and Financial Officer of Tiziana Life Sciences, will deliver a corporate presentation highlighting the Company's recent clinical and corporate updates....
|
|
|
|
|
|
|
|
|
21.05.26 - 17:06
|
Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial (GlobeNewswire EN)
|
|
|
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that patient enrollment has been completed in its randomized, double-blind, placebo-controlled Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Topline data is expected in late Q3 of 2026, and will also to be presented at the 10th joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and ECTRIMS meeting in Toronto, Canada in October 2026....
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
